ALK-positive NSCLC
FDA Approves Alecensa as Adjuvant Treatment for ALK-Positive NSCLC
The FDA approved alectinib (Alecensa, Genentech) for adjuvant treatment following tumor resection in patients with ...
APRIL 22, 2024
FDA Approves Lorbrena for ALK-Positive Metastatic NSCLC
The FDA granted regular approval to lorlatinib (Lorbrena, Pfizer) for metastatic anaplastic lymphoma ...
MARCH 11, 2021
FDA Approves Alunbrig for Treatment of ALK-Positive, Metastatic NSCLC
The FDA approved the use of brigatinib (Alunbrig, Ariad) for adults with anaplastic lymphoma kinase (ALK)-positive, ...
JUNE 1, 2020
Load more